Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 7/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.40 |
| ▸ | RARB | P10826 | 3/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | RARA | P10276 | 1/20 | 0.35 |
| ▸ | RARG | P13631 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12740331 | 0.93 | RARB (0.37) | NAAADRD4SIGMAR1TMEM97RARB | |
| SCHEMBL12740327 | 0.89 | NAAA (0.48) | NAAADRD4SIGMAR1TMEM97 | |
| SCHEMBL12736732 | 0.88 | FFAR4 (0.38) | NAAARARBFFAR4PPARGPPARA | |
| SCHEMBL12740300 | 0.88 | FFAR4 (0.38) | NAAARARBFFAR4PPARGPPARA | |
| SCHEMBL12733910 | 0.88 | SPHK1 (0.41) | RARBFFAR4 | |
| SCHEMBL12718964 | 0.88 | NAAA (0.48) | NAAADRD4SIGMAR1TMEM97PPARA | |
| SCHEMBL12740333 | 0.88 | NAAA (0.48) | NAAADRD4SIGMAR1TMEM97 | |
| SCHEMBL12739849 | 0.87 | RARB (0.37) | RARBFFAR4PPARGPPARA | |
| SCHEMBL12740326 | 0.86 | FFAR4 (0.38) | NAAARARBFFAR4RARARARG | |
| SCHEMBL12740330 | 0.86 | NAAA (0.39) | NAAADRD4SIGMAR1TMEM97FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | NAAA 3997/4885DRD4 97/4885SIGMAR1 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.